Brief: Hansoh Pharmaceutical Says NMPA Grants Breakthrough-Therapy Designation To Hs-20093 With Adebrelimab
16/04/2026 12:31
April 16 (Reuters) - Hansoh Pharmaceutical 3692.HK: NMPA GRANTS BREAKTHROUGH-THERAPY DESIGNATION TO HS-20093 WITH ADEBRELIMAB Further company coverage: 3692.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion